Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors

ConclusionsFurther development of JTX-4014 is warranted as a monotherapy or in combination with other innovative cancer therapies.Trial registration numberNCT03790488, December 31 2018.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research